Elizabeth Moore
Family · Norwich, NYNPI 1548812092
Payments from drug & device makers
Across 495 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Boehringer Ingelheim$1K
- GSK$799
- Novo Nordisk$757
- Lilly USA, LLC$753
- Amgen$537
- plus $3K from 26 others
What the payments were for
- Food & beverage$8,63999%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 82 | $1,669 |
| Boehringer Ingelheim | 51 | $1,015 |
| GSK | 58 | $799 |
| Novo Nordisk | 43 | $757 |
| Lilly USA, LLC | 48 | $753 |
| Amgen | 29 | $537 |
| Astellas Pharma US Inc | 21 | $414 |
| Merck | 22 | $384 |
| AstraZeneca | 15 | $306 |
| Pfizer | 21 | $304 |
| Johnson & Johnson | 17 | $265 |
| Biohaven Pharmaceuticals, Inc. | 11 | $240 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $185 |
| Exact Sciences | 6 | $118 |
| Amarin Pharma, Inc. | 6 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $104 |
| Novartis | 5 | $97 |
| Otsuka America Pharmaceutical, Inc. | 5 | $87 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $80 |
| Lundbeck LLC | 4 | $72 |
| Corium, LLC | 4 | $67 |
| Bayer | 4 | $62 |
| Abbott | 3 | $61 |
| Paratek Pharmaceuticals, Inc. | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 3 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
| Metacel Pharmaceuticals LLC | 1 | $11 |
How this compares
$8,738 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 111 | $111,479 |
| OzempicSemaglutide | 67 | $100,141 |
| FarxigaDapagliflozin Propanediol | 51 | $56,189 |
| EliquisApixaban | 29 | $46,598 |
| TrulicityDulaglutide | 30 | $46,048 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $41,994 |
| RybelsusSemaglutide | 11 | $29,433 |
| XareltoRivaroxaban | 19 | $27,928 |
| JanuviaSitagliptin Phosphate | 14 | $17,981 |
| MyrbetriqMirabegron | 12 | $16,488 |
| Emgality PenGalcanezumab-Gnlm | 13 | $13,952 |
| VascepaIcosapent Ethyl | 20 | $11,497 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $8,332 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $7,125 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 140 | $6,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $757 | $129,57478 claims |
| Boehringer IngelheimJardiance | $1,015 | $111,479111 claims |
| AstraZenecaFarxiga, Symbicort | $306 | $64,52180 claims |
| PfizerEliquis | $304 | $46,59829 claims |
| Lilly USA, LLCTrulicity | $753 | $46,04830 claims |
| GSKTrelegy Ellipta | $799 | $41,99464 claims |
| Johnson & JohnsonXarelto | $265 | $27,92819 claims |
| MerckJanuvia | $384 | $17,98114 claims |
| Astellas Pharma US IncMyrbetriq | $414 | $16,48812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Norwich
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.